A 12-week open-label trial gave 9.6 mg/day of hexaraphane/6-MSITC to 15 people with ME/CFS and reported significant pre-post changes in cognitive function, brain fog, headache frequency, pain, vitality, and performance status.

ME/CFS is not ordinary tiredness. It is a serious condition involving disabling fatigue lasting at least six months, post-exertional malaise, brain fog, pain, and other symptoms. This article reviews diagnosis, proposed mechanisms, links with Long COVID, and current care.

Amyloid-β is a peptide associated with Alzheimer’s disease. This article explains how it is produced and cleared, why accumulation may begin 20–30 years before symptoms, how it relates to tau, and research on sleep, exercise, and diet.

“We retrieved oocytes, but none were of good quality.” “My AMH level is low.” These concerns point to a problem...

“What was that person’s name again?” Many people find themselves asking this question more often after their 60s.Age-related memory decline...

Aging is a natural process that affects everyone. In recent years, however, the way researchers understand aging has changed substantially....

Japan has entered an era of population super-aging. According to estimates from the Ministry of Health, Labour and Welfare, approximately...

At NOMON & Co., we review the latest research on aging every day, guided by our vision of building a...

NOMON & Co. is committed to creating a society in which “productive aging” is the norm. Rather than focusing solely...